• Personalis ctDNA Test Paves Way for Medicare Reimbursement in Breast Cancer

    Mar 06 | Diagnostics World | A retrospective study from Personalis for its NeXT Personal test, an ultra-sensitive circulating tumor DNA (ctDNA) test for cancer patients and survivors, has been published in Annals of Oncology. The study was conducted with researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK. More

  • Methylation Monitoring Predicts Pan-Cancer Outcomes

    Mar 05 | Diagnostics World | In a paper published last month in Nature Scientific Reports, authors validate Northstar Response, BillionToOne's novel tissue-free circulating tumor DNA (ctDNA) liquid biopsy test that enables physicians to monitor cancer treatment response in Stage III-IV cancers with a blood draw. More

  • Pan-European Genomic Reanalysis Project Turns Up Over 500 Diagnoses

    Mar 04 | Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant. More

  • Dovetail’s Platform for Oncology Research, Novel iPSC Foundry, More

    Feb 27 | Diagnostics World | Dovetail Genomics announced its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis; Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry; and more. More

  • Follow the Money: Radionuclide Therapies, GIP Antagonists for Obesity, More

    Feb 26 | Diagnostics World | A transcontinental collaborative effort brought together 300 experts from 12 European countries and Canada to try and crack the genetic cause of thousands of unsolved rare disease cases. Through data-sharing and genetic reanalysis, this “coalition of the willing” has most recently succeeded in providing more than 500 patients with a long-awaited diagnosis—and peace of mind to unaffected family members about whether they carry the risk variant. More

  • University of Cambridge Develops ‘Sleep Pajamas’ For Monitoring Sleep Disorders

    Feb 20 | Diagnostics World | Researchers at the University of Cambridge have developed washable and comfortable ‘smart pajamas’ to help monitor sleep disorders at home. The pajamas negate the need for sticky patches, monitoring equipment, or visiting sleep clinics for specialty tests. More

  • LinusBio Launches ClearStrand-ASD That Detects Autism With a Single Hair Strand

    Feb 13 | Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians. More

  • Dual Biomarker Assay for Pancreatic Cancer to be Studied in CLIA Lab

    Feb 11 | Diagnostics World | Two glycans are better than one when it comes to detecting pancreatic cancer that currently lacks a biomarker capable of accurately and reliably spotting the disease. The gold standard biomarker CA19-9, approved by the U.S. Food and Drug Administration (FDA) for monitoring response to treatment, correctly identifies only 44% of cases but the addition of CA199.STRA ramped that up to 71% while maintaining a low false positive rate in a recent case control study. More

  • Wearables Could Enable Continuous Monitoring of Inflammatory Diseases

    Feb 05 | Diagnostics World | Physiological changes in the body driven by inflammation, as happens with inflammatory bowel disease (IBD) and rheumatoid arthritis, can be “easily and passively” measured with commercially available wearable devices, according to gastroenterologist Robert Hirten, M.D., associate professor of medicine and artificial intelligence and human health at the Icahn School of Medicine at Mount Sinai. More

  • High-Value Opportunities for Multimodal AI in Clinical Care and Research

    Feb 04 | Diagnostics World | Amid an industrywide shortage of workers and hospital capacity, a multimodal artificial intelligence (AI) platform providing real-time visibility into the clinical picture for patients is finding a national audience with health systems big and small who want to “make the right thing the easy thing to do” for their overburdened clinicians. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more